Leichlingen, Germany

Haireddin Jacobi


Average Co-Inventor Count = 3.3

ph-index = 3

Forward Citations = 58(Granted Patents)


Location History:

  • Leichlingen, Rhineland, DE (1978)
  • Leichlingen, DE (1976 - 1985)

Company Filing History:


Years Active: 1976-1985

Loading Chart...
15 patents (USPTO):Explore Patents

Title: Haireddin Jacobi: Innovator in Pharmaceutical Chemistry

Introduction

Haireddin Jacobi is a notable inventor based in Leichlingen, Germany. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 15 patents. His work primarily focuses on the development of novel compounds with potential therapeutic applications.

Latest Patents

Among his latest patents, Jacobi has developed quinazolinone derivatives. This invention relates to quinazolinone derivatives of a specific formula and processes for their production. The invention also includes pharmaceutical compositions containing these compounds as active ingredients, highlighting their use as anti-inflammatory agents. Another significant patent involves 7,8,9,10-tetrahydrothieno[3,2-e]pyrido[4,3-b]indole compounds. This invention pertains to new compounds that influence the central nervous system, with a unique ring system that has not been previously described in the literature.

Career Highlights

Throughout his career, Jacobi has worked with prominent companies such as Troponwerke GmbH & Co. KG and Bayer Aktiengesellschaft. His experience in these organizations has allowed him to refine his expertise in pharmaceutical innovations and contribute to various research projects.

Collaborations

Jacobi has collaborated with notable colleagues, including Wolfgang Opitz and Karl-Heinz Boltze. These partnerships have further enriched his research and development efforts in the pharmaceutical sector.

Conclusion

Haireddin Jacobi's contributions to pharmaceutical chemistry through his innovative patents and collaborations underscore his importance in the field. His work continues to influence the development of new therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…